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Abstract
Prostate cancer (PCa) is the second most common cancer in men. Androgen deprivation therapy (ADT) leads to tumor
involution and reduction of tumor burden. However, tumors eventually reemerge that have overcome the absence of
gonadal androgens, termed castration resistant PCa (CRPC). Theories underlying the development of CRPC include
androgen receptor (AR) mutation allowing for promiscuous activation by non-androgens, AR amplification and
overexpression leading to hypersensitivity to low androgen levels, and/or tumoral uptake and conversion of adrenally
derived androgens. More recently it has been proposed that prostate tumor cells synthesize their own androgens through
de novo steroidogenesis, which involves the step-wise synthesis of androgens from cholesterol. Using the in vivo LNCaP PCa
xenograft model, previous data from our group demonstrated that a hypercholesterolemia diet potentiates prostatic tumor
growth via induction of angiogenesis. Using this same model we now demonstrate that circulating cholesterol levels are
significantly associated with tumor size (R=0.3957, p=0.0049) and intratumoral levels of testosterone (R=0.41, p=0.0023)
in LNCaP tumors grown in hormonally intact mice. We demonstrate tumoral expression of cholesterol uptake genes as well
as the spectrum of steroidogenic enzymes necessary for androgen biosynthesis from cholesterol. Moreover, we show that
circulating cholesterol levels are directly correlated with tumoral expression of CYP17A, the critical enzyme required for de
novo synthesis of androgens from cholesterol (R=0.4073, p=0.025) Since hypercholesterolemia does not raise circulating
androgen levels and the adrenal gland of the mouse synthesizes minimal androgens, this study provides evidence that
hypercholesterolemia increases intratumoral de novo steroidogenesis. Our results are consistent with the hypothesis that
cholesterol-fueled intratumoral androgen synthesis may accelerate the growth of prostate tumors, and suggest that
treatment of CRPC may be optimized by inclusion of cholesterol reduction therapies in conjunction with therapies targeting
androgen synthesis and the AR.
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Introduction
Prostatic malignancies, benign prostatic hyperplasia, and
normal prostate tissues lose homeostatic control over cholesterol
level with age, synthesize cholesterol at a high rate, and thereby
accumulate excess levels of cholesterol [1,2,3]. The overall
consequence of this cholesterol accumulation on prostate physi-
ology is unknown, but a role for high levels of serum cholesterol in
PCa incidence and progression has been suggested by a number of
epidemiological and pre-clinical studies [4,5,6,7,8,9]. While high
fat/high cholesterol ‘Western’ diets have been linked to PCa
incidence and progression in some reports, a role for specific
dietary components in disease progression has not been clearly
established [10,11]. Studies examining groups of nutritional
components eaten together suggest that diets with a high content
of cholesterol-rich, processed and/or red meat may be associated
with higher PCa incidence [12,13]. In addition, observational
studies of cholesterol-lowering drug use (i.e. HMG-CoA reductase
inhibitors, aka statins) and cancer incidence, which include large
numbers of PCa patients and a substantial number with advanced
disease, show an inverse association between statin use and PCa
incidence and/or progression, including a significant reduction
in risk of advanced disease with long term statin use
[14,15,16,17,18,19,20,21,22,23,24]. Although not all studies
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suggests that cholesterol plays a role in PCa progression, with its
most likely role being a factor in the progression to advanced
disease.
We have demonstrated that hypercholesterolemic diets
stimulate growth of LNCaP human PCa xenografts [9,28].
Tumors in the hypercholesterolemic environment accumulated
more cholesterol in their membranes, exhibited lower levels of
apoptosis, had enhanced activation of Akt (a kinase linked to
aggressive PCa) [29,30,31,32], and were more angiogenic
[9,28]. We also demonstrated that a hypocholesterolemic diet
has the opposite effect, inhibiting the growth of prostatic
tumors. In explaining these results, we hypothesized that
cholesterol might directly contribute to tumor growth by
altering signal transduction pathways [1,28,33], consistent with
the role of cholesterol in organizing liquid ordered membrane
domains [34]. But other explanations for the effect of
hypercholesterolemia on PCa risk warrant careful consideration.
In particular, one important new hypothesis is that cholesterol
affects PCa growth by serving as a precursor for intratumoral
androgen synthesis.
Androgen Deprivation Therapy (ADT) is the primary treatment
strategy for advanced metastatic PCa [35,36,37]. However,
despite initial efficacy as well as maintenance of castrate levels of
circulating androgens, progression to castration resistant prostate
cancer (CRPC) invariably occurs [35,36]. Theories regarding
development of the castration-resistant phenotype include: 1) gene
amplification and/or mutation of the AR, allowing the receptor to
be sensitive to low levels of androgen [38,39,40,41,42,43,44]; 2)
residual androgen production from the adrenals [45]; and 3)
promiscuous receptor-ligand interactions [40,46].
More recently, several lines of evidence are converging on the
hypothesis that PCa cells synthesize their own androgens,
including in the castrate environment [47,48,49], in sufficient
quantities to activate the AR. Prior studies [47] have shown that
all of the enzymes necessary for de novo steroidogenesis are
expressed in LNCaP tumor xenografts, and that androgen-starved
PCa cells are capable of synthesizing DHT from acetic acid,
suggesting that the entire mevalonate-steroidogenic pathway is
intact in this model system [47]. In a prior report, we
demonstrated that the full complement of enzymes comprising
the steroidogenic pathways are present in a significant subset of
human primary and metastatic PCas examined [49], implying that
de novo androgen synthesis is not merely an experimental
phenomenon, but rather a potential underlying cause of disease
progression in the hormone-repressed state. In addition, this and
other studies established that serum and tissue steroid hormone
concentrations are not correlated, indicating that detailed analysis
of tissue hormones is necessary to evaluate the effects of cholesterol
on tissue steroidogenesis.
In the current study using tumors partially described previously
[9], we follow-up on our prior reports demonstrating that a
hypercholesterolemic diet promotes, while hypocholesterolemic
diet retards, the growth of prostate tumors in vivo, by demonstrat-
ing that the level of circulating cholesterol is associated with tumor
growth and the intratumoral level of androgens (especially
testosterone (T)). This is the first study of any kind demonstrating
that circulating cholesterol levels influence tumor androgen levels
and the first to demonstrate that pharmacological lowering of
cholesterol reduces the level of tumor androgens. These new data
suggest that cholesterol-based management of prostate cancer
progression may be an effective strategy at reducing tumor growth
in patients.
Materials and Methods
Mice and tumor xenografts
All procedures were done in compliance with Children’s
Hospital Boston’s animal care and use policies; protocol 07-11-
1416R covering these procedures was approved by the IACUC of
Children’s Hospital Boston. 5 week old SCID mice obtained from
the Massachusetts General Hospital were fed a low fat/no
cholesterol diet (LFNC) (Research Diets, New Brunswick, NJ diet
# D12102). After two weeks, blood was drawn from the
saphenous tail vein and the serum cholesterol concentration
measured using the Infinity Cholesterol Liquid Stable Reagent
(Thermo Electron Corp.). The mice were then divided into high
fat/high cholesterol diet (HFHC) (Research Diets, diet # D12108)
and LFNC diet groups 6 ezetimibe (30 mg/kg(mouse weight)/
day; Schering-Plough, New Brunswick, NJ, added to powdered
food) and the mice continued on these diets for two weeks prior to
tumor implantation. Mice were not fed a libitum, but instead diets
were fed to mice isocalorically with each mouse receiving
17.32 kcal/day. These diets do not produce any difference in
mouse body weight between the cohorts [9] (data not shown).
Xenografts were initiated by injecting LNCaP (2610
6 per site)
with 1:1 volume of Matrigel (BD BioSciences, San Jose, CA) into
the 4 dorsal quadrants of each mouse. To eliminate any injection
bias, mice were randomized prior to implantation and the
implanter was blinded to the mouse cohort assignment. Tumors
were measured daily from the appearance of the first palpable
tumors and the mice were sacrificed prior to achieving the
maximum tumor burden (<13 days post implantation). Terminal
bleeds were taken (cardiac puncture) for serology (triglyceride,
bilirubin and other liver function tests were performed in the Dept.
of Laboratory Medicine, Children’s Hospital Boston, androgen
levels were determined by a testosterone EIA, Diagnostic Systems
Laboratories, Webster, TX). Tumors were removed, measured,
weighed and either placed in OCT solution (Tissue-Tek,
Torrance, CA) or snap frozen. For the purpose of analysis, each
of the 4 tumors per mouse was regarded as a separate entity.
There was no correlation of tumor size amongst the 4 tumors and
there was no evidence of a dominant effect of one tumor on the
others. A prior report by our group contains details on aspects of
the growth and histology of these tumors [9].
Cell culture
LNCaP human prostate cancer cells (American Type Culture
Collection, Manassas, VA), which do not express either caveolin
[33] or PTEN [50] were cultured in RPMI (Invitrogen, Carlsbad,
CA) media supplemented with 10% FBS and 1% Penicillin/
Streptomycin in 5% CO2 at 37uC.
Tumor androgen analysis
30–50 mg pieces of snap frozen randomly chosen tumors, <13
from each diet cohort, were analyzed for tissue androgen levels by
mass spectrometry (MS) using methods we have recently described
[51]. This procedure resulted in a lower limit of quantitation of
1 pg per sample for T and DHT respectively. Intra-assay
coefficients of variation generated using human serum for high,
mid and low-range samples were 3.5, 3.1 and 3.8% for T and 6.3,
4.3 and 15.8% for DHT respectively.
RNA isolation and quantitative RT-PCR
RNA was isolated and prepared for quantitative PCR (qRT-
PCR) as previously described [49]. cDNA was generated in a
random-primed reverse transcription reaction, and qRT-PCR
reactions were performed in triplicate using an Applied Biosystems
Cholesterol, Steroidogenesis and Prostate Cancer
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pair and SYBR Green PCR master mix (Applied Biosystems, Foster
City, CA). Specificity of amplification was assessed based on melting
point of the dissociation curve. Primer sequences were as previously
published [49] as well as including the following: SR-B1 Forward
CCTCACAGGGTCCCTCAGATTAT, Reverse TTCCAGTA-
GAAAAGGGTCACAGG; LDLR Forward TTGCCTCTGAA-
ATGCCTCTTCT, Reverse ATCATTCTCCCAAAAAGCGT-
TG; STARD3 Forward GAAAGAGTCTGGGACCCTTGTTG,
Reverse CCTGGGAGAGGCAGAGATTCAT; and CYB5A For-
ward AGATTCAGAAGCACAACCACAGC, Reverse TTAAAA-
CTTCTTCCCCACCAGGA. Although no new sequence data was
generated, all new data has been deposited in GenBank.
Statistics
Unpaired two sample t-tests were used to compare differences in
samples above or below the median. One way ANOVA was used
to assess variance across quartiles, with a post test for linear trend
between mean values in each quartile. Linear regression was used
for assessment of correlations. In all cases, p values,0.05 were
considered significant. For analysis of qRT-PCR data, the mean
cycle threshold (Ct) for each gene was normalized to expression of
the housekeeping gene RPL13A in the same sample (delta Ct).
Results
We have created an innovative isocaloric diet approach
allowing us to determine the specific effects of cholesterol in mice,
by generating 4 murine cohorts, each with a different serum
cholesterol level (<140, 160, 180 & 200 mg/dL; Fig. 1A). As we
have shown [9], this approach permits us to study hyper- and
hypocholesterolemia simultaneously without affecting liver func-
tion, insulin levels, animal weight, or circulating steroid hormone
levels. The basic design of our cholesterol-targeting approach
combines a diet regimen with a pharmaceutical agent, ezetimibe
(Zetia), an FDA approved drug that specifically blocks cholesterol
uptake in the intestine, thereby lowering serum cholesterol levels.
In this scheme we use a low fat/no cholesterol diet (LFNC) and a
high fat/high cholesterol diet (HFHC) (w/o sodium cholate) 6
ezetimibe (30 mg/kg/d added to powdered food). Ezetimibe is a
specific antagonist of NPC1L1, the bona fide gut cholesterol
transporter [52,53,54,55]. Ezetimibe has no known target other
than NPC1L1, and NPC1L1 is expressed only in the intestine and
in hepatocytes (in humans), but not by tumor cells.
As we previously reported [9] mice fed the HFHC diet
developed larger tumors (weight and volume), whereas mice fed
the LFNC diet had smaller tumors. The addition of ezetimibe to
either diet reduced tumor size. The combination of the LFNC
diet+ezetimibe had the most significant effect on tumor growth (vs.
the HFHC diet w/o ezetimibe). Statistical evaluation demonstrat-
ed that both the diet (p=0.048) and ezetimibe (p=0.035)
produced significant independent, additive, but not synergistic,
effects on tumor growth (both volume and weight). Serology
showed no liver dysfunction, no statistical differences in triglyc-
eride (TG) levels (trending higher in the HFHC cohort), & no
statistical differences in insulin or IGF-1 levels (not shown).
Importantly, the HFHC diet did not increase serum T levels over
the LFNC diet (Fig. 1B), as expected, since circulating cholesterol
does not influence serum androgen levels [56].
Our prior analysis only concerned whether HFHC and LFNC
diets 6 ezetimibe were associated with tumor growth, not whether
tumor growth was a function of circulating cholesterol, per se. In
our current analysis we unbound the groups and determined more
precisely the relationship between circulating cholesterol level and
tumor characteristics, as cholesterol level does not correspond
directly to diet group, i.e. while HFHC raised cholesterol levels for
the whole group, not every animal was in the highest cholesterol
quartile, and similarly, while the LFNC diet+ezetimibe diet cohort
had the lowest cholesterol level as a group not every animal in the
cohort was in the lowest cholesterol quartile. Thus, while the
HFHC cohort corresponds well to the highest quartile of
cholesterol (9/10 were in Q4), the other quartiles contain a
mixture of animals/tumors from the other 3 treatment groups
(data not shown).
To determine the relationship between circulating cholesterol
levels and tumor growth we analyzed tumor data from the 4
cohorts in aggregate, and plotted tumor size (weight and volume)
vs. serum cholesterol level. Both tumor weight (Fig. 2A) and
volume (Fig. 2B) were significantly larger in animals with levels of
circulating cholesterol above vs. below the median, and demon-
strated significant linear trends over the quartiles of cholesterol
(Fig. 2C,D, respectively). For example, tumor weight ranged from
a mean of 0.7960.3 gm in tumors in the lowest quartile of serum
cholesterol (Q1) to 1.3260.6 gm in the highest quartile (Q4;
Figure 1. Serum cholesterol and testosterone levels in murine cohorts receiving cholesterol targeted treatment. (A) Mean cholesterol
levels (with standard deviation and range) in mice randomized to 12 weeks of treatment with the indicated combinations of a low fat/no cholesterol
diet (LFNC) or high fat/high cholesterol diet (HFHC) 6 ezetimibe (drug). One way ANOVA with a post test for linear trend was used to compare values
in the four treatment groups. P values,0.05 were considered significant. (B) Measurement of serum testosterone levels by ELISA in mice receiving
the indicated HFHC or LFNC diet (n=10/group). Data are presented as testosterone (T) levels (ng/ml) vs. diet group 6 SE. Differences between mice
fed the two diets were not statistically significant (unpaired two sample t-test).
doi:10.1371/journal.pone.0030062.g001
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higher cholesterol levels promote tumor growth.
Although modulating serum cholesterol did not alter circulating
T levels (Fig. 1B), LNCaP tumor cells express all the enzymes
required to synthesize androgens from cholesterol (i.e. de novo
steroidogenesis), giving us the opportunity to determine if
circulating cholesterol levels influence intratumoral androgen
levels. Snap frozen samples from 52 LNCaP tumors (,n=13 in
each treatment group) were analyzed by MS for levels of T and
DHT. Overall, mean tumor T levels were 2.7161.66 pg/mg
(range 0.44–7.39 pg/mg), and mean DHT levels were
0.6160.16 pg/mg (range 0.25–0.96 pg/mg). This ratio of T to
DHT is similar to that observed by Locke et al in a previous study
of castration sensitive LNCaP tumors prior to castration [47].
To explore the relationship between cholesterol, tumor
androgens, and tumor growth we analyzed all the tumor data in
aggregate, and plotted tumor T vs. tumor weight or tumor
cholesterol. As demonstrated in Fig. 3, mean tumor T levels were
higher in animals with circulating cholesterol levels above
compared to below the median (Fig. 3A; 2.161.2 vs. 3.461.8,
p=0.0047), as well as higher in the larger tumors (Fig. 3B;
2.261.4 vs. 3.361.8, p=0.025). Similarly, tumor T levels
demonstrated significant linear trends over the quartiles of both
serum cholesterol (Fig. 3C; p=0.0042) and tumor weight
(Fig. 3D; p=0.037). Cholesterol quartile analysis indicated that
DHT levels also trended higher as cholesterol level rose, but did
not reach statistical significance (Figure S1). Notably, linear
regression demonstrated significant correlations between serum
cholesterol and tumor weight (Fig. 4A, R=0.3957, p=0.0049),
serum cholesterol and tumor T (Fig. 4B, R=0.4179, p=0.0023),
and near significance for serum cholesterol and tumor DHT
(Fig. 4C, R=0.2613, p=0.06).
To determine whether the xenograft tumors expressed the
steroidogenic genes necessary to generate T and DHT from
circulating cholesterol, we profiled the tumors for expression of
transcripts encoding each enzyme in the steroid bio-synthetic
pathway, as well as several genes related to cholesterol uptake and
mitochondrial transport (Fig. 5A). The majority of tumors had
demonstrable expression of cholesterol transport genes (Fig. 5B),
as well as the critical enzymes required for de novo steroidogenesis
(Fig. 5C). While the majority of these genes did not demonstrate a
significant correlation with cholesterol level, their expression levels
are consistent with values previously reported in human PCa
metastases with elevated tumor androgens [49], and in PCa
xenograft models [57]. Of particular importance, serum choles-
terol levels were significantly correlated with tumoral expression of
17 a-hydroxylase (CYP17A), the central enzyme required for de
novo synthesis of androgens from cholesterol (Fig. 5D, R=0.4073,
Figure 2. Growth of LNCaP xenograft tumors in relation to serum cholesterol levels. Mean tumor weight (A) and volume (B) (with
standard deviation and range) in mice with cholesterol levels above or below the median serum cholesterol level. P values from unpaired two sample
t-tests. Mean tumor weight (C) and volume (D) (with standard deviation and range) in mice grouped by quartile of serum cholesterol levels. P values
from one way ANOVA of mean values in the four quartiles, with a post test for linear trend. The mean cholesterol levels in tumors above or below the
median, or in each quartile of cholesterol, and the number of mice in each group, are indicated below the x-axis in each graph.
doi:10.1371/journal.pone.0030062.g002
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significant inverse correlation with the LDLR (low density
lipoprotein receptor; R=20.512, p=0.0009), demonstrating that
although these tumors accumulated cholesterol, certain normal
feedback mechanisms regulating cholesterol uptake were func-
tional (data not shown).
Figure 3. Tumor testosterone levels in LNCaP xenografts in relation to serum cholesterol levels and tumor weight. Mean testosterone
levels (with standard deviation and range) measured by mass spectrometry in tumors from mice with cholesterol levels above or below the median
cholesterol level (A), or in tumors above or below the median weight (B). The mean cholesterol levels and tumor weights in tumors above or below
the median, and the number of mice in each group, are indicated below the x-axis in each graph. P values from unpaired two sample t-tests. Mean
testosterone levels in tumors from mice grouped by quartile of serum cholesterol (C), or in tumors grouped by quartile of tumor weight (D). P values
from one way ANOVA of mean values in the four quartiles, with a post test for linear trend. The mean cholesterol levels and tumor weights in tumors
in each quartile of cholesterol or weight, and the number of mice in each group, are indicated below the x-axis in each graph.
doi:10.1371/journal.pone.0030062.g003
Figure 4. Correlation of serum cholesterol levels with tumor weight, tumors androgens and expression of CYP17A in LNCaP
xenografts. The correlation of serum cholesterol levels with tumor weight (A), testosterone (B) and DHT (C) in aggregated tumors from all four
treatment cohorts (n=52). Tumor androgens were determined by mass spectrometry. Correlation coefficients and p values from linear regression
analysis.
doi:10.1371/journal.pone.0030062.g004
Cholesterol, Steroidogenesis and Prostate Cancer
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30 years ago Geller et al [58] first reported that sufficient
androgen to drive the AR remained in the prostate after castration
[58]. Indeed, the positive results of a phase III trial using the
CYP17 inhibitor, abiraterone, in men with CRPC demonstrates
that for many men, CRPC remains androgen-driven [59,60].
Modern studies also suggest that PCa cells in men receiving ADT
have androgen levels high enough to activate the AR despite
castrate levels of circulating androgens [59,61,62,63,64,65,66].
The mechanisms responsible for maintenance of functional levels
of T and DHT in CRPC tumors are unknown, but have been
hypothesized to reflect the uptake and conversion of adrenal
androgens or de novo synthesis of T from cholesterol or earlier
precursors.
Here we show that elevations in serum cholesterol are directly
correlated with tumor size, tumor T levels and expression of the
key steroidogenic enzyme, CYP17A, in the castration sensitive
LNCaP xenograft model, suggesting that one source of intratu-
moral androgen in prostate tumors is via de novo synthesis from
circulating cholesterol. In mice the adrenal glands express little to
no CYP17A, the essential enzyme required to convert pregnen-
olone to androstenedione, and consequently produce little to no
androgen or androgen precursors (e.g. androstenediol) [47,67].
The relative lack of adrenal contribution to androgen levels in this
model, and the absence of diet-induced changes in circulating T
(Fig. 1) suggest that the primary mechanism of the diet-induced
increase in tumor androgen concentrations is due to de novo
intratumoral synthesis from exogenous cholesterol.
In our prior report on the growth-promoting effects of
cholesterol on prostate tumors [9] we determined that one effect
of hypercholesterolemia was to increase tumor angiogenesis, which
was associated with a substantial decrease in the expression of
thrombonspondin-1 (TSP1) an angiogenesis inhibitor. Interesting-
ly, TSP1 expression is suppressed by androgen [68]. Patients
receiving androgen ablation therapy (ADT) were reported to
exhibit a substantial increase in TSP1 expression in comparison to
prostate cancers in patients not receiving ADT. The present data
demonstrating that hypercholesterolemia increases androgen
expression may explain why hypercholesterolemia also reduces
TSP1 expression and increases angiogenesis, thereby facilitating
tumor growth.
It is of particular interest that a targeted low fat, low cholesterol
diet was able to modulate tumor androgen profiles in the
hormonally intact environment in which tumor growth is not
dependant on non-testicular sources of androgen. It appears that
once a tumor has steroidogenic potential (as has been demon-
Figure 5. Expression of steroidogenic enzymes necessary for de novo synthesis of androgens from cholesterol in LNCaP xenografts.
(A) Enzymes and intermediates in the steroid bio-synthetic pathway leading from cholesterol to the formation of testosterone and DHT. LDLR and SR-
B1 mediate cholesterol uptake; STAR and STARD3 mediate transport of cholesterol across the mitochondrial membrane where steroidogenesis is
initiated. CYB5A is an important cofactor for the lyase activity of CYP17A. (B) Transcript profiling of tumors from all 4 treatment groups by qRT-PCR for
the androgen receptor (AR), the androgen regulate gene PSA, and genes involved in cholesterol transport. (C) Transcript profiling for the expression
of steroidogenic genes and the CYB5 cofactor. The mean cycle threshold (CT) for detection of each transcript was normalized to expression of the
housekeeping gene RPL13A in the same sample (delta or dCT). (D) The correlation of serum cholesterol levels with transcript expression of CYP17A as
measured by qRT-PCR. Correlation coefficients and p values from linear regression analysis.
doi:10.1371/journal.pone.0030062.g005
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modifiable, factor for tumor growth through up-regulating
androgen synthesis, even when intratumoral androgen synthesis
is not absolutely required. A number of studies have shown that
use of cholesterol-lowering statin drugs, which inhibit the rate
limiting enzyme in cholesterol synthesis, HMG-CoA reductase,
reduce the risk of advanced PCa, especially when used for more
than 5 years, and usually many years prior to any evidence of
cancer [15,17,18,19,20,22,23,24]. This suggests that application of
a cholesterol-lowering strategy prior to cancer development may
reduce the risk of advanced PCa. Interestingly, a phase I–II trial
testing a high dose (up to 45 mg/kg/day) of lovastatin (a
commonly prescribed statin) in patients with CRPC that had
failed prior therapies had no effect on the cancer, suggesting that
intervention using a cholesterol-based approach was attempted too
late for a positive response [69]. Together with our results this
prior study suggests that the timing of treatment may be critical,
and that application of a cholesterol-lowering strategy once PCa
has become aggressive may be too late to prevent or treat CRPC.
Although, we have no direct evidence in human patients, our
results suggest that cholesterol-lowering therapies might have a
particular growth inhibitory effect on early stage prostate tumors
that have a positive steroidogenic profile. It remains to be
determined if these hypothesized benefits will be achievable in a
human patient cohort.
It is important to point out that although we are confident in
our analyses, we are reluctant to extrapolate these studies to
human patients, as there are substantial differences between our
pre-clinical xenograft model and PCas found in human patients: 1)
the vascular bed in which the tumor is growing, and thus aspects of
angiogenic potential, are different in the subcutaneous flank vs. the
prostate; 2) inflammatory processes that likely contribute to PCa
growth and aggressiveness are not recapitulated in the xenograft
model; 3) tumors do no go through various stages of development
from PIN (prostate intraepithelial neoplasia) to frank adenocarci-
noma in the xenograft model; and 4) although this limitation is not
generally appreciated, the conservation of growth factors,
receptors, adhesion molecules etc. is not 100% between mouse
and human, and thus certain regulatory factors may not work
efficiently in a xenograft model.
In summary, here we demonstrate the novel observation that
circulating cholesterol levels influence tumor androgen levels and
that pharmacological lowering of cholesterol reduces the level of
tumor androgens. Several studies have demonstrated that CRPC
tumors can express the full complement of steroidogenic enzymes
[49,66], consistent with the hypothesis that a subset of castration-
resistant prostate cancers can carry on de novo steroidogenesis. Our
findings suggest cholesterol-targeting therapy may inhibit the
growth of aggressive prostate cancers via attenuation of intracrine
steroidogenesis and, further, that this approach may synergize with
therapies directly targeting androgen synthesis and the AR.
Supporting Information
Figure S1 Tumor DHT levels in LNCaP xenografts in
relation to serum cholesterol levels and tumor weight.
Mean DHT levels (with standard deviation and range) measured
by mass spectrometry in tumors from mice grouped by quartile of
serum cholesterol (A), or in tumors grouped by quartile of tumor
weight (B). P values from one way ANOVA of mean values in the
four quartiles, with a post test for linear trend. The mean
cholesterol levels and tumor weights in tumors in each quartile of
cholesterol or weight, and the number of mice in each group, are
indicated below the x-axis in each graph.
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